Need Help? Chat Now With a Live Representative!

Why “CRA-centricity” Matters For Your Rare Disease Clinical Trial

Why “CRA-centricity” Matters For Your Rare Disease Clinical Trial

Why “CRA-centricity” Matters For Your Rare Disease Clinical Trial

August 4, 2017

Rare disease clinical trials also require extraordinary customer service—sometimes even including package delivery. In one case, each treatment dose cost more than $3,500, required constant refrigeration within a narrow temperature range, and had to be checked in and out to document protocol compliance and chain of custody—requirements beyond even FedEx’s legendary capabilities. Often, the task fell to the trial’s clinical research associates (CRAs), who went well beyond their job description to ensure the trial succeeded.

Read More

Breaking Ground in Medicine: Our Role in the Approval of Bivigam by ADMA Biologics

Breaking Ground in Medicine: Our Role in the Approval of Bivigam by ADMA Biologics

Since 2004, ARG has been working in the immunology space, using our individualized approach to optimize the likelihood of successful […]

March 8, 2024
ARG and Humacyte Collaborate on Human Acellular Vessel (HAV) Program Advancements in Vascular Trauma

ARG and Humacyte Collaborate on Human Acellular Vessel (HAV) Program Advancements in Vascular Trauma

CHARLOTTESVILLE, VIRGINIA – ARG (Atlantic Research Group) proudly announces its ongoing collaboration with Humacyte, a leading biotechnology company, on the […]

February 23, 2024
Revolutionizing Treatment: Our Contribution to Humacyte’s Latest Innovation

Revolutionizing Treatment: Our Contribution to Humacyte’s Latest Innovation

In 2014, ARG began working with Humacyte on their Human Acellular Vessel (HAV) interposition graft program, which included three separate […]

February 7, 2024
GO TO TOP